PDF(Pubmed)
Abstract：
UNASSIGNED: The aim of the present study was to evaluate the clinical impact of the Global Immune-Nutrition-Information Index (GINI) in patients with gastric cancer (GC) who received curative treatment and to clarify the potential of the GINI as a biomarker.
UNASSIGNED: Patients who underwent curative resection for GC at Yokohama City University between 2005 and 2020 were selected based on their medical records. The GINI was calculated as follows: GINI=[C-reactive protein × platelet × monocyte × neutrophil]/[albumin × lymphocyte].
UNASSIGNED: A total of 258 patients were included in this study. Of these, 169 patients were categorized into the GINI-low group and 89 into the GINI-high group using a cut-off value of 1,730. The three- and five-year overall survival (OS) rates were 86.4% and 78.4%, respectively, in the GINI-low group, and 66.4% and 58.3% in the GINI-high group (p<0.001). In a multivariate analysis for OS, the GINI was identified as an independent prognostic factor [hazard ratio (HR)=1.772; 95% confidence interval (CI)=1.053-2.979, p=0.031]. Similar results were observed for RFS. In addition, the GINI affected the perioperative clinical course, including postoperative surgical complications and postoperative adjuvant treatment.
UNASSIGNED: The GINI is a promising biomarker for the treatment and management of GC.
UNASSIGNED: Patients who underwent curative resection for GC at Yokohama City University between 2005 and 2020 were selected based on their medical records. The GINI was calculated as follows: GINI=[C-reactive protein × platelet × monocyte × neutrophil]/[albumin × lymphocyte].
UNASSIGNED: A total of 258 patients were included in this study. Of these, 169 patients were categorized into the GINI-low group and 89 into the GINI-high group using a cut-off value of 1,730. The three- and five-year overall survival (OS) rates were 86.4% and 78.4%, respectively, in the GINI-low group, and 66.4% and 58.3% in the GINI-high group (p<0.001). In a multivariate analysis for OS, the GINI was identified as an independent prognostic factor [hazard ratio (HR)=1.772; 95% confidence interval (CI)=1.053-2.979, p=0.031]. Similar results were observed for RFS. In addition, the GINI affected the perioperative clinical course, including postoperative surgical complications and postoperative adjuvant treatment.
UNASSIGNED: The GINI is a promising biomarker for the treatment and management of GC.
摘要：
■本研究的目的是评估全球免疫营养信息指数（GINI）对接受治愈性治疗的胃癌（GC）患者的临床影响，并阐明GINI作为生物标志物的潜力。
■根据病历选择2005年至2020年在横滨市立大学接受GC治愈性切除术的患者。GINI计算如下:GINI=[C反应蛋白×血小板×单核细胞×中性粒细胞]/[白蛋白×淋巴细胞]。
■本研究共纳入258例患者。其中,使用1,730的截止值，将169名患者分为GINI低组，将89名患者分为GINI高组。3年和5年总生存率(OS)分别为86.4%和78.4%,分别,在吉尼低组中，GINI高组分别为66.4%和58.3%(p<0.001)。在操作系统的多变量分析中，GINI被确定为独立的预后因素[风险比(HR)=1.772;95%置信区间(CI)=1.053-2.979,p=0.031].对于RFS观察到类似的结果。此外,GINI影响围手术期临床过程，包括术后并发症和术后辅助治疗。
■GINI是治疗和管理GC的有前途的生物标志物。
■根据病历选择2005年至2020年在横滨市立大学接受GC治愈性切除术的患者。GINI计算如下:GINI=[C反应蛋白×血小板×单核细胞×中性粒细胞]/[白蛋白×淋巴细胞]。
■本研究共纳入258例患者。其中,使用1,730的截止值，将169名患者分为GINI低组，将89名患者分为GINI高组。3年和5年总生存率(OS)分别为86.4%和78.4%,分别,在吉尼低组中，GINI高组分别为66.4%和58.3%(p<0.001)。在操作系统的多变量分析中，GINI被确定为独立的预后因素[风险比(HR)=1.772;95%置信区间(CI)=1.053-2.979,p=0.031].对于RFS观察到类似的结果。此外,GINI影响围手术期临床过程，包括术后并发症和术后辅助治疗。
■GINI是治疗和管理GC的有前途的生物标志物。
